Full-Life Technologies

Executive Summary

Full-Life Technologies is a Shanghai-based radiopharmaceutical company focused on developing targeted radionuclide therapies and diagnostics for oncology. Founded in 2021, the company leverages a proprietary drug delivery platform designed to enhance tumor targeting while minimizing off-target effects, addressing key challenges in the radiopharmaceutical field. Full-Life aims to build a fully integrated pipeline spanning isotope production to novel therapeutic radiopharmaceuticals, positioning itself as a vertically integrated player in the growing China radiopharma market. The company is currently in Phase 2 clinical development, indicating that its lead candidates have advanced beyond initial proof-of-concept and are generating early efficacy and safety data. Given the increasing global interest in radioligand therapy and China's push for innovation in oncology, Full-Life Technologies represents a promising but early-stage opportunity in the precision oncology space. Despite limited public pipeline details, Full-Life's strategic focus on in-house isotope production and proprietary delivery technology could provide a competitive edge in a market where supply chain control is critical. The company's private status and lack of disclosed financials make valuation challenging, but the radiopharmaceutical sector has seen significant acquisition and partnership activity. Key risks include regulatory hurdles specific to China, competition from established players, and the inherent technical challenges of radionuclide development. Near-term value drivers will likely center on clinical data readouts, strategic partnerships, and progress toward regulatory filings. With a conviction score of 65, Full-Life Technologies is a speculative opportunity with high upside potential if its platform delivers on targeting and safety promises.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Clinical Data Readout for Lead Program60% success
• Q4 2026Strategic Partnership or Licensing Deal for Isotope Supply or Co-Development70% success
• Q2 2027IND Filing for Next-Generation Radiopharmaceutical Candidate55% success